Department of pulmonary medicine, Indira Gandhi Medical College, Shimla, Himachal Pradesh, India.
Department of Medical and Pediatric Oncology, Kerudi Cancer Hospital, Bagalkot, Karnataka, India.
Clin Respir J. 2021 Dec;15(12):1259-1274. doi: 10.1111/crj.13438. Epub 2021 Aug 30.
The SARS-CoV-2 is a new coronavirus responsible for the COVID-19 disease and has caused the pandemic worldwide. A large number of cases have overwhelmed the healthcare system worldwide. The COVID-19 infection has been associated with a heightened risk of thromboembolic complications. Various mechanisms are leading to the high thrombotic risk in COVID-19 patients such as inflammation, endotheliitis, hyperviscosity, and hypercoagulability. We searched PubMed, EMBASE, and CINAHL from January 2020 to December 2020. We used the following search terms: COVID-19, coagulopathy, and thrombosis. We reviewed the epidemiology, clinical features, mechanisms, and treatment of COVID-19-associated coagulopathy.
SARS-CoV-2 是一种新型冠状病毒，可引发 COVID-19 疾病，并在全球范围内引发大流行。大量病例使全球医疗系统不堪重负。COVID-19 感染与血栓栓塞并发症的风险增加有关。多种机制导致 COVID-19 患者存在高血栓形成风险，如炎症、血管内皮炎、高黏滞血症和高凝状态。我们检索了 2020 年 1 月至 12 月期间的 PubMed、EMBASE 和 CINAHL，使用了以下检索词：COVID-19、凝血障碍和血栓形成。我们回顾了 COVID-19 相关凝血障碍的流行病学、临床特征、机制和治疗方法。
